Sara I. Pai, Ph.D. - Publications

Affiliations: 
2002 Johns Hopkins University, Baltimore, MD 
Area:
Medicine and Surgery, Immunology, Oncology

85 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Chung C, Dimitrios Colevas A, Gibson M, Adkins D, Sukari A, Wirth L, Burtness B, Bauman J, Rodriguez C, Worden F, Saba N, Glisson B, Dunn L, Seiwert T, Agensky L, ... ... Pai S, et al. 438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer Journal For Immunotherapy of Cancer. 9: A468-A468. DOI: 10.1136/jitc-2021-sitc2021.438  0.341
2020 Pai SI, Faquin WC, Sadow PM, Pittet MJ, Weissleder R. New technology on the horizon: Fast analytical screening technique FNA (FAST-FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. Cancer Cytopathology. PMID 32841527 DOI: 10.1002/Cncy.22305  0.319
2020 Pai SI, Cesano A, Marincola FM. The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. Cancer Treatment and Research. 180: 173-195. PMID 32215870 DOI: 10.1007/978-3-030-38862-1_6  0.383
2020 Banik G, Betts CB, Liudahl SM, Sivagnanam S, Kawashima R, Cotechini T, Larson W, Goecks J, Pai SI, Clayburgh DR, Tsujikawa T, Coussens LM. High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. Methods in Enzymology. 635: 1-20. PMID 32122539 DOI: 10.1016/Bs.Mie.2019.05.039  0.381
2020 Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, ... ... Pai SI, et al. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology. PMID 32042168 DOI: 10.1038/S41587-019-0404-8  0.378
2020 Wolkow N, Jakobiec FA, Afrogheh AH, Kidd M, Eagle RC, Pai SI, Faquin WC. PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications. Ophthalmic Plastic and Reconstructive Surgery. PMID 31990894 DOI: 10.1097/Iop.0000000000001585  0.301
2020 Pai SI, Marincola FM. Peripheral Circulating CD45RAFOXP3 T Regulatory (T) II Cells Provide a Window into the Activity of Intratumoral T Cells. Trends in Cancer. 6: 3-6. PMID 31952778 DOI: 10.1016/J.Trecan.2019.11.003  0.36
2020 Pai S, Adkins D, Wirth L, Chung C, Gibson M, Sukari A, Worden F, Colevas D, Saba N, Burtness B, Rodriguez C, Bauman J, Glisson B, Dunn L, Suri A, et al. 354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer Journal For Immunotherapy of Cancer. 8: A379-A379. DOI: 10.1136/jitc-2020-sitc2020.0354  0.323
2019 Pai SI, Cohen EEW, Lin D, Fountzilas G, Kim ES, Mehlhorn H, Baste N, Clayburgh D, Lipworth L, Resteghini C, Shara N, Fujii T, Zhang J, Stokes M, Wang H, et al. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of Translational Medicine. 17: 429. PMID 31878938 DOI: 10.1186/S12967-019-02182-1  0.382
2019 Ishida E, Lee J, Campbell JS, Chakravarty PD, Katori Y, Ogawa T, Johnson L, Mukhopadhyay A, Faquin WC, Lin DT, Wirth LJ, Pierce RH, Pai SI. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. Cancer Immunology, Immunotherapy : Cii. PMID 31243491 DOI: 10.1007/S00262-019-02357-1  0.408
2019 Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). Journal For Immunotherapy of Cancer. 7: 96. PMID 30944020 DOI: 10.1186/S40425-019-0578-0  0.315
2019 Wolkow N, Jakobiec FA, Afrogheh AH, Eagle RC, Pai SI, Faquin WC. PD-L1 and PD-L2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. American Journal of Ophthalmology. PMID 30633894 DOI: 10.1016/J.Ajo.2018.12.020  0.345
2019 Pai SI, Friedman AD, Franco R, Muniappan A, Park JC, Campbell NP, Krantz SB, Song PC, Bove M, Carroll TL, Faquin WC, O'Neill AM, Wirth LJ. A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and/or pulmonary involvement. Journal of Clinical Oncology. 37: 2502-2502. DOI: 10.1200/Jco.2019.37.15_Suppl.2502  0.335
2018 Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, ... ... Pai SI, et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity. PMID 30552023 DOI: 10.1016/J.Immuni.2018.09.024  0.366
2018 Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA. Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer. Genome Medicine. 10: 54. PMID 30029671 DOI: 10.1186/S13073-018-0569-7  0.337
2018 Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocrine Pathology. PMID 29372535 DOI: 10.1007/S12022-018-9514-Y  0.347
2018 Pai SI, Jack Lee J, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncology. 77: 92-97. PMID 29362132 DOI: 10.1016/J.Oraloncology.2017.12.014  0.32
2018 Pai SI, Clayburgh D, Patel M, Bell RB, Yueh B, Lin D, Halliwell K, Turan T, Samayoa J, Cairns B, Park JC, Leidner RS, Wirth LJ, Saba NF, Shin DM, et al. ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine. Journal of Clinical Oncology. 36: 6052-6052. DOI: 10.1200/Jco.2018.36.15_Suppl.6052  0.355
2017 Mattox A, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng Y, ... ... Pai SI, et al. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-L1+ TAMs. Cancer Research. PMID 28947422 DOI: 10.1158/0008-5472.Can-16-3453  0.325
2017 Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, ... ... Pai SI, et al. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head & Neck. PMID 28945296 DOI: 10.1002/Hed.24911  0.301
2017 Mohan S, Pai SI, Bhattacharyya N. Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. The Laryngoscope. PMID 28150306 DOI: 10.1002/Lary.26443  0.313
2017 Osho AA, Azzoli CJ, Pai S, Mino-Kenudson M, Faquin WC, Huynh TG, Lanuti M, Mathisen DJ, Muniappan A. Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. The Annals of Thoracic Surgery. 103: e123-e125. PMID 28109369 DOI: 10.1016/J.Athoracsur.2016.08.021  0.361
2017 Pai SI, Lee JJ, Carey TE, Westra WH, Ferrone S, Moore C, Shin DM, Ferris RL. Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients. Journal of Clinical Oncology. 35: 6058-6058. DOI: 10.1200/Jco.2017.35.15_Suppl.6058  0.316
2017 Wirth LJ, Burtness B, Mehra R, Bauman JR, Lee J, Smith NMS, Lefranc-Torres A, Westra WH, Bishop JA, Faquin WC, Lin DT, Pai SI. IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC. Journal of Clinical Oncology. 35: 6053-6053. DOI: 10.1200/Jco.2017.35.15_Suppl.6053  0.406
2017 Pai SI, Cohen E, Lin D, Fountzilas G, Kim ES, Mehlhorn H, Baste N, Clayburgh D, Lipworth L, Resteghini C, Shara N, Fujii T, Zhang J, Stokes M, Lawrence D, et al. A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN). Journal of Clinical Oncology. 35: 6040-6040. DOI: 10.1200/Jco.2017.35.15_Suppl.6040  0.355
2017 Alamoud K, Sadykov K, Kartha V, Monti S, Belkina A, Snyder-Cappione J, Pai S, Kukuruzinska M. Abstract 803: Targeting β-catenin/CBP signaling in OSCC Cancer Research. 77: 803-803. DOI: 10.1158/1538-7445.Am2017-803  0.332
2016 Walline HM, Carey TE, Goudsmit CM, Bellile EL, D'souza G, Peterson LA, McHugh JB, Pai SI, Lee JJ, Shin DM, Ferris RL. High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Molecular Cancer Research : McR. PMID 27899422 DOI: 10.1158/1541-7786.Mcr-16-0255  0.349
2016 Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncology. PMID 27503244 DOI: 10.1016/J.Oraloncology.2016.08.001  0.335
2016 Brotherton JM, Jit M, Gravitt PE, Brisson M, Kreimer AR, Pai SI, Fakhry C, Monsonego J, Franceschi S. Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines. International Journal of Cancer. Journal International Du Cancer. PMID 26916230 DOI: 10.1002/Ijc.30063  0.366
2016 Peng S, Mattox A, Best SR, Barbu AM, Burns JA, Akpeng B, Jeang J, Yang B, Ishida E, Hung CF, Wu TC, Pai SI. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes. Cancer Immunology, Immunotherapy : Cii. PMID 26759151 DOI: 10.1007/S00262-016-1793-X  0.423
2015 Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncology. PMID 26094591 DOI: 10.1016/J.Oraloncology.2015.05.007  0.365
2015 Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE. In-Situ tumor vaccination: Bringing the fight to the tumor. Human Vaccines & Immunotherapeutics. 0. PMID 26055074 DOI: 10.1080/21645515.2015.1049779  0.367
2015 Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. Plos One. 10: e116389. PMID 25560237 DOI: 10.1371/Journal.Pone.0116389  0.426
2015 Pai S, Smith D, Peng S, Ishida E, Akpeng B, Hung CF, Wu TC. OC-015: Therapeutic HPV vaccine increases sensitivity of poorly immunogenic tumor to anti-PD-1 monotherapy Radiotherapy and Oncology. 114: 12. DOI: 10.1016/S0167-8140(15)34775-7  0.401
2014 D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2408-15. PMID 24778397 DOI: 10.1200/Jco.2014.55.1341  0.352
2014 Smith DF, Maleki Z, Coughlan D, Gooi Z, Akpeng B, Ogawa T, Bishop JA, Frick KD, Agrawal N, Gourin CG, Ha PK, Koch WM, Richmon JD, Westra WH, Pai SI. Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay. Oral Oncology. 50: 600-4. PMID 24630260 DOI: 10.1016/J.Oraloncology.2014.02.011  0.379
2014 Wu CY, Yang LH, Yang HY, Knoff J, Peng S, Lin YH, Wang C, Alvarez RD, Pai SI, Roden RB, Hung CF, Wu TC. Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 644-57. PMID 24300786 DOI: 10.1158/1078-0432.Ccr-13-1334  0.394
2014 Sanguineti G, Pai S, Agbahiwe H, Ricchetti F, Westra W, Sormani MP, Clemente S, Califano J. HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V. Acta Oncologica (Stockholm, Sweden). 53: 662-8. PMID 24274389 DOI: 10.3109/0284186X.2013.858825  0.35
2014 Nanda R, Plimack ER, Dees EC, Gupta S, Berger R, Elfiky A, Pusztai L, Buisseret L, Geva R, Pai SI, Pathiraja K, Iannone R, Gause C, Brown H, Houp J, et al. A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors. Journal of Clinical Oncology. 32: TPS3119-TPS3119. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps3119  0.403
2014 Seiwert TY, Burtness B, Weiss J, Gluck I, Eder JP, Pai SI, Dolled-Filhart M, Emancipator K, Pathiraja K, Gause C, Iannone R, Brown H, Houp J, Cheng JD, Chow LQM. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. Journal of Clinical Oncology. 32: 6011-6011. DOI: 10.1200/Jco.2014.32.15_Suppl.6011  0.404
2013 Lin BM, Wang H, D'Souza G, Zhang Z, Fakhry C, Joseph AW, Drake VE, Sanguineti G, Westra WH, Pai SI. Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. Cancer. 119: 3462-71. PMID 23861037 DOI: 10.1002/Cncr.28250  0.369
2013 Pai SI. Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. Oncoimmunology. 2: e24065. PMID 23762795 DOI: 10.4161/Onci.24065  0.43
2013 Pai SI. Mission impossible: how HPV-associated head and neck cancers escape a primed immune response. Oral Oncology. 49: 723-5. PMID 23643070 DOI: 10.1016/J.Oraloncology.2013.03.453  0.392
2013 Bishop JA, Ogawa T, Stelow EB, Moskaluk CA, Koch WM, Pai SI, Westra WH. Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract. The American Journal of Surgical Pathology. 37: 836-44. PMID 23598962 DOI: 10.1097/Pas.0B013E31827B1Cd6  0.373
2013 Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, Pardoll DM, Pai SI. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Research. 73: 1733-41. PMID 23288508 DOI: 10.1158/0008-5472.Can-12-2384  0.563
2013 Bishop JA, Guo TW, Smith DF, Wang H, Ogawa T, Pai SI, Westra WH. Human papillomavirus-related carcinomas of the sinonasal tract. The American Journal of Surgical Pathology. 37: 185-92. PMID 23095507 DOI: 10.1097/Pas.0B013E3182698673  0.382
2013 Joseph AW, Ogawa T, Bishop JA, Lyford-Pike S, Chang X, Phelps TH, Westra WH, Pai SI. Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas. Oral Oncology. 49: 244-8. PMID 23062994 DOI: 10.1016/J.Oraloncology.2012.09.009  0.406
2013 Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunology, Immunotherapy : Cii. 62: 171-82. PMID 23011589 DOI: 10.1007/S00262-012-1322-5  0.407
2013 D'Souza G, Gross ND, Pai SI, Haddad RI, Gillison ML, Posner MR. Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Cra6031  0.355
2013 Coughlan D, O’Connor T, Pai S, Westra W, Frick K, O’Neill C, Keogh I. Oncopolicy in high-income countries can make a difference in HPV-related Head and Neck Cancer Journal of Cancer Policy. 1: e49-e51. DOI: 10.1016/J.Jcpo.2013.07.003  0.362
2012 Pai SI. HPV-associated head and neck cancers. Otolaryngologic Clinics of North America. 45: xi-xii. PMID 22793861 DOI: 10.1016/J.Otc.2012.05.003  0.371
2012 Best SR, Niparko KJ, Pai SI. Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers. Otolaryngologic Clinics of North America. 45: 807-22. PMID 22793854 DOI: 10.1016/J.Otc.2012.04.005  0.364
2012 Zaboli D, Tan M, Gogineni H, Lake S, Fan K, Zahurak ML, Messing B, Ulmer K, Zinreich ES, Levine MA, Tang M, Pai SI, Blanco RG, Saunders JR, Best SR, et al. Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients. International Journal of Otolaryngology. 2012: 754191. PMID 22778748 DOI: 10.1155/2012/754191  0.309
2012 Fan KY, Gogineni H, Zaboli D, Lake S, Zahurak ML, Best SR, Levine MA, Tang M, Zinreich ES, Saunders JR, Califano JA, Blanco RG, Pai SI, Messing B, Ha PK. Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. Annals of Surgical Oncology. 19: 1980-7. PMID 22290566 DOI: 10.1245/S10434-012-2219-4  0.318
2012 Bishop JA, Ogawa T, Chang X, Illei PB, Gabrielson E, Pai SI, Westra WH. HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. The American Journal of Surgical Pathology. 36: 142-8. PMID 22173119 DOI: 10.1097/Pas.0B013E3182395C7B  0.389
2012 Bishop JA, Maleki Z, Valsamakis A, Ogawa T, Chang X, Pai SI, Westra WH. Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. Cancer Cytopathology. 120: 18-25. PMID 21751428 DOI: 10.1002/Cncy.20175  0.373
2012 Lyford-Pike S, Peng S, Taube JM, Westra WH, Akpeng B, Wang H, Drake CG, Chen L, Topalian SL, Pardoll DM, Pai SI. PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers. Journal of Clinical Oncology. 30: 5506-5506. DOI: 10.1200/Jco.2012.30.15_Suppl.5506  0.417
2011 Anderson KS, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai SI, Longtine J, McClean M, LaBaer J, Kelsey KT, Posner M. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. British Journal of Cancer. 104: 1896-905. PMID 21654689 DOI: 10.1038/Bjc.2011.171  0.369
2011 Park IS, Chang X, Loyo M, Wu G, Chuang A, Kim MS, Chae YK, Lyford-Pike S, Westra WH, Saunders JR, Sidransky D, Pai SI. Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. Cancer Prevention Research (Philadelphia, Pa.). 4: 207-17. PMID 21292634 DOI: 10.1158/1940-6207.Capr-10-0147  0.38
2011 Best SR, Ha PK, Blanco RG, Saunders JR, Zinreich ES, Levine MA, Pai SI, Walker M, Trachta J, Ulmer K, Murakami P, Thompson R, Califano JA, Messing BP. Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. Head & Neck. 33: 1727-34. PMID 21246640 DOI: 10.1002/Hed.21657  0.372
2011 Wu A, Zeng Q, Kang TH, Peng S, Roosinovich E, Pai SI, Hung CF. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer Gene Therapy. 18: 304-312. PMID 20981112 DOI: 10.1038/Gt.2010.151  0.434
2011 Smith I, Rosenblatt E, Sanguineti G, Bishop JA, Richmon JD, Pai S. Extracapsular Extension in Lymph Node Metastasis from HPV-Associated Squamous Cell Carcinoma of the Oropharynx Otolaryngology-Head and Neck Surgery. 145. DOI: 10.1177/0194599811416318A80  0.386
2011 Chang X, Cho YG, Park I, Shao C, Ha P, Pai SI, Sidransky D, Kim MS. Abstract 4799: Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma Cancer Research. 71: 4799-4799. DOI: 10.1158/1538-7445.Am2011-4799  0.302
2011 Kumar R, Bishop J, Pai S, Westra W, Califano J, Hennessey P, Marur S, Forastiere A, Sanguineti G. Defining the Risk of Extra-Capsular Extension (ECE) in Patients with Early T-stage, Node-positive, HPV-related Oropharyngeal Carcinoma International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.791  0.355
2010 Kim D, Hoory T, Monie A, Wu A, Hsueh WT, Pai SI, Hung CF. Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. Journal of Biomedical Science. 17: 61. PMID 20659328 DOI: 10.1186/1423-0127-17-61  0.3
2010 Kang TH, Noh KH, Kim JH, Bae HC, Lin KY, Monie A, Pai SI, Hung CF, Wu TC, Kim TW. Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Research. 70: 3062-70. PMID 20395201 DOI: 10.1158/0008-5472.Can-09-3856  0.361
2010 Peng S, Best SR, Hung CF, Loyo M, Lyford-Pike S, Flint PW, Tunkel DE, Saunders JR, Wu TC, Pai SI. Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. The Laryngoscope. 120: 504-10. PMID 20025042 DOI: 10.1002/Lary.20745  0.393
2009 Kang TH, Chung JY, Monie A, Pai SI, Hung CF, Wu TC. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. Gene Therapy. 17: 531-40. PMID 19940864 DOI: 10.1038/Gt.2009.152  0.363
2009 Hillel AT, Fakhry C, Pai SI, Williams MF, Blanco RGF, Zinreich ES, Levine MA, Westra WH, Saunders JR, Ha PK. Selective versus comprehensive neck dissection after chemoradiation for advanced oropharyngeal squamous cell carcinoma Otolaryngology - Head and Neck Surgery. 141: 737-742. PMID 19932847 DOI: 10.1016/J.Otohns.2009.09.010  0.325
2009 Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 27: 5450-9. PMID 19622402 DOI: 10.1016/J.Vaccine.2009.07.005  0.429
2009 Chuang CM, Monie A, Wu A, Pai SI, Hung CF. Combination of viral oncolysis and tumor-specific immunity to control established tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4581-8. PMID 19584165 DOI: 10.1158/1078-0432.Ccr-08-2685  0.343
2009 Sedaghat AR, Zhang Z, Begum S, Palermo R, Best S, Ulmer KM, Levine M, Zinreich E, Messing BP, Gold D, Wu AA, Niparko KJ, Kowalski J, Hirata RM, Saunders JR, ... ... Pai SI, et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. The Laryngoscope. 119: 1542-9. PMID 19522004 DOI: 10.1002/Lary.20533  0.401
2009 Noh KH, Kang TH, Kim JH, Pai SI, Lin KY, Hung CF, Wu TC, Kim TW. Activation of Akt as a mechanism for tumor immune evasion. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 439-47. PMID 19107122 DOI: 10.1038/Mt.2008.255  0.381
2009 Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annual Review of Pathology. 4: 49-70. PMID 18729723 DOI: 10.1146/Annurev.Pathol.4.110807.092158  0.326
2008 Loyo M, Pai SI. The molecular genetics of laryngeal cancer. Otolaryngologic Clinics of North America. 41: 657-72, v. PMID 18570952 DOI: 10.1016/J.Otc.2008.01.019  0.317
2008 Wu AA, Niparko KJ, Pai SI. Immunotherapy for head and neck cancer. Journal of Biomedical Science. 15: 275-89. PMID 18392689 DOI: 10.1007/S11373-008-9247-X  0.403
2008 Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pai SI, Califano JA, Tufano RP, Koch WM. Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head & Neck. 30: 898-903. PMID 18383529 DOI: 10.1002/Hed.20796  0.374
2007 Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, Hung CF, Trimble C, Lim JS, Kim TW, Wu TC. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Research. 67: 802-11. PMID 17234792 DOI: 10.1158/0008-5472.Can-06-2638  0.398
2004 Kim TW, Hung CF, Zheng M, Boyd DA, He L, Pai SI, Wu TC. A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. Journal of Biomedical Science. 11: 493-9. PMID 15153784 DOI: 10.1007/Bf02256098  0.4
2004 Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, Wu TC. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Therapy. 11: 1011-8. PMID 14985791 DOI: 10.1038/Sj.Gt.3302252  0.43
2004 Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine. 21: 4036-42. PMID 12922140 DOI: 10.1016/S0264-410X(03)00275-5  0.567
2002 Cheng WF, Hung CF, Pai SI, Hsu KF, He L, Ling M, Wu TC. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. Journal of Biomedical Science. 9: 675-87. PMID 12432234 DOI: 10.1159/000067285  0.406
2001 Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM, Tsuchiya H. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. The Journal of Experimental Medicine. 193: 839-46. PMID 11283156 DOI: 10.1084/Jem.193.7.839  0.668
2000 Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Therapy. 7: 726-33. PMID 10822298 DOI: 10.1038/sj.gt.3301160  0.511
1999 Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Human Gene Therapy. 10: 2727-40. PMID 10584920 DOI: 10.1089/10430349950016474  0.721
Show low-probability matches.